| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 7173 | 2016 |
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes Spectrum 25 (3), 154-171, 2012 | 6741 | 2012 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes … DM Nathan, JB Buse, MB Davidson, E Ferrannini, RR Holman, R Sherwin, ... Diabetes care 32 (1), 193-203, 2009 | 5745* | 2009 |
| Williams textbook of endocrinology E-Book S Melmed, KS Polonsky, PR Larsen, HM Kronenberg Elsevier Health Sciences, 2015 | 4344 | 2015 |
| Effects of intensive blood-pressure control in type 2 diabetes mellitus ACCORD Study Group New England Journal of Medicine 362 (17), 1575-1585, 2010 | 4318 | 2010 |
| Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) MJ Davies, DA D’Alessio, J Fradkin, WN Kernan, C Mathieu, G Mingrone, ... Diabetes care 41 (12), 2669-2701, 2018 | 4188 | 2018 |
| Follow-up report on the diagnosis of diabetes mellitus S Genuth, K Alberti, P Bennett, J Buse, R DeFronzo, R Kahn, J Kitzmiller, ... Diabetes care 26 (11), 3160-3168, 2003 | 3817 | 2003 |
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes care 38 (1), 140-149, 2015 | 3692 | 2015 |
| The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes R Kahn, J Buse, E Ferrannini, M Stern Diabetes care 28 (9), 2289-2304, 2005 | 3639 | 2005 |
| Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, ... New England Journal of Medicine 373 (3), 232-242, 2015 | 3165 | 2015 |
| Strategies for multivessel revascularization in patients with diabetes ME Farkouh, M Domanski, LA Sleeper, FS Siami, G Dangas, M Mack, ... New England journal of medicine 367 (25), 2375-2384, 2012 | 2168 | 2012 |
| Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association … DM Nathan, JB Buse, MB Davidson, RJ Heine, RR Holman, R Sherwin, ... Diabetes care 29 (8), 1963-1972, 2006 | 2082 | 2006 |
| Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association JB Buse, HN Ginsberg, GL Bakris, NG Clark, F Costa, R Eckel, V Fonseca, ... Circulation 115 (1), 114-126, 2007 | 2017 | 2007 |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ... New England Journal of Medicine 377 (13), 1228-1239, 2017 | 2012 | 2017 |
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American … JS Skyler, R Bergenstal, RO Bonow, J Buse, P Deedwania, EAM Gale, ... Circulation 119 (2), 351-357, 2009 | 1972 | 2009 |
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) JB Buse, J Rosenstock, G Sesti, WE Schmidt, E Montanya, JH Brett, ... The Lancet 374 (9683), 39-47, 2009 | 1954 | 2009 |
| 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study … JB Buse, DJ Wexler, A Tsapas, P Rossing, G Mingrone, C Mathieu, ... Diabetes care 43 (2), 487-493, 2020 | 1826 | 2020 |
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes JB Buse, RR Henry, J Han, DD Kim, MS Fineman, AD Baron, ... Diabetes care 27 (11), 2628-2635, 2004 | 1652 | 2004 |
| Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator JB Buse, AC Moses US Patent 6,591,125, 2003 | 1537 | 2003 |
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study DJ Drucker, JB Buse, K Taylor, DM Kendall, M Trautmann, D Zhuang, ... The Lancet 372 (9645), 1240-1250, 2008 | 1251 | 2008 |
